Use of a sustained-release formulation of oxprenolol and cyclopenthiazide ('Trasidrex') in the management of hypertension: a general practice study.

An open study was carried out in general practice on 678 hypertensive patients being treated with a beta-blocker but who still had resting diastolic blood pressures greater than 100 mmHg. Previous treatment was stopped and substituted with 1 or 2 tablets daily of a fixed combination product containing 160 mg oxprenolol hydrochloride in a sustained-release formulation plus 0.25 mg cyclopenthiazide per tablet. After 4-weeks' treatment on this regimen, blood pressure levels fell significantly, from 179/108 mmHg to 155/93 mmHg, without any increase in the reporting of unpleasant side-effects.
AuthorsW A Forrest
JournalCurrent medical research and opinion (Curr Med Res Opin) Vol. 6 Issue 8 Pg. 559-63 ( 1980) ISSN: 0300-7995 [Print] ENGLAND
PMID7389387 (Publication Type: Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Diuretics
  • Sodium Chloride Symporter Inhibitors
  • Oxprenolol
  • Cyclopenthiazide
  • Adult
  • Aged
  • Blood Pressure (drug effects)
  • Cyclopenthiazide (adverse effects, therapeutic use)
  • Delayed-Action Preparations
  • Diuretics
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypertension (drug therapy)
  • Male
  • Middle Aged
  • Oxprenolol (adverse effects, therapeutic use)
  • Pulse (drug effects)
  • Sodium Chloride Symporter Inhibitors (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: